Müller Morgante L, Epifanio A, Spina E, et al. 2004. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol, 27:153–6. Muhlack S, Przuntek H, Müller T. 2006. Transdermal rivastigmine treatment does not worsen impaired performance of complex motions in patients with Alzheimer’s disease. Pharmacopsychiatry, 39:16–19. Müller T, Kuhn W, Schulte T, et al. 2003a. Intravenous amantadine sulphate application improves the performance of complex but not simple motor tasks in patients with Parkinson’s disease. Neurosci Lett, 339:25–8. Müller T, Meisel M, Russ H, et al. 2003b. Motor impairment inﬂuences Farnsworth-Munsell 100 Hue test error scores in Parkinson’s disease patients. J Neurol Sci, 213:61–5. Müller T, Schafer S, Kuhn W, et al. 2000. Correlation between tapping and inserting of pegs in Parkinson’s disease. Can J Neurol Sci, 27:311–15. Pal PK, Lee CS, Samii A, et al. 2001. Alternating two ﬁnger tapping with contralateral activation is an objective measure of clinical severity in Parkinson’s disease and correlates with PET. Parkinsonism Relat Disord, 7:305–9. Parkinson Study Group. 1999. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med, 340:757–63. Poewe W, Wolters E, Emre M, et al. 2006. Long-term benefits of rivastigmine in dementia associated with Parkinson’s disease:an active treatment extension study. Mov Disord, 21:456–61. Polinsky RJ. 1998. Clinical pharmacology of rivastigmine:a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease. Clin Ther, 20:634–47. Priano L, Gasco MR, Mauro A. 2006. Transdermal treatment options for neurological disorders:impact on the elderly. Drugs Aging, 23:357–75. Richard IH, Justus AW, Greig NH, et al. 2002. Worsening of motor function and mood in a patient with Parkinson’s disease after pharmacologic challenge with oral rivastigmine. Clin Neuropharmacol, 25:296–9. Ritchie CW, Ames D, Clayton T, et al. 2004. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Am J Geriatr Psychiatry, 12:358–69. Rosler M, Anand R, Cicin-Sain A, et al. 1999. Efﬁcacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ, 318:633–8. Saft C, Andrich J, Meisel NM, et al. 2003. Assessment of complex movements reﬂects dysfunction in Huntington’s disease. J Neurol, 250:1469–74. Saft C, Andrich J, Meisel NM, et al. 2004. Congruent deterioration of complex and simple movements in patients with Huntington’s disease. J Neural Transm, (Suppl):97–104. Spencer CM, Noble S. 1998. Rivastigmine. A review of its use in Alzheimer’s disease. Drugs Aging, 13:391–411. Takeda A, Loveman E, Clegg A, et al. 2006. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer’s disease. Int J Geriatr Psychiatry, 21:17–28. Tariot PN. 2001. Maintaining cognitive function in Alzheimer disease: how effective are current treatments? Alzheimer Dis Assoc Disord, 15(Suppl 1):S26–S33. Tiraboschi P, Hansen LA, Alford M, et al. 2000. Cholinergic dysfunction in diseases with Lewy bodies. Neurology, 54:407–11. van Dyck CH. 2004. Understanding the latest advances in pharmacologic interventions for Alzheimer’s disease. CNS Spectr, 9(Suppl 5):24–8. Van Hilten JJ, Middelkoop HA, Kuiper SI, et al. 1993. Where to record motor activity:an evaluation of commonly used sites of placement for activity monitors. Electroencephalogr. Clin Neurophysiol, 89:359–62. van Vugt JP, Siesling S, Piet KK, et al. 2001. Quantitative assessment of daytime motor activity provides a responsive measure of functional decline in patients with Huntington’s disease. Mov Disord, 16:481–8. Weinstock M. 1999. Selectivity of cholinesterase inhibition–Clinical implications for the treatment of Alzheimer’s disease. CNS Drugs, 12:307–23. Werber EA, Rabey JM. 2001. The beneﬁcial effect of cholinesterase inhibitors on patients suffering from Parkinson’s disease and dementia. J Neural Transm, 108:1319–25. Wilkinson DG, Francis PT, Schwam E, et al. 2004. Cholinesterase inhibitors used in the treatment of Alzheimer’s disease: the relationship between pharmacological effects and clinical efﬁcacy. Drugs Aging, 21:453–78. Wilkinson DG, Passmore AP, Bullock R, et al. 2002. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer’s disease. Int J Clin Pract, 56:441–6. Winblad B, Beusterien KM, Thomas SK, et al. 2006. Caregivers prefer patches to capsules: results from a 24-week placebo-controlled study of rivastigmine (IDEAL trial). Hot topic session ICAD 2006. 218 Neuropsychiatric Disease and Treatment 2007:3(2)